Phone worldwide: +49 2103 29 11711
Phone U.S.: +1 240 686 2222
Phone worldwide: +49 2103 29 11826
Phone U.S.: +1 240 686 7425
QIAGEN on the web
Annual General Meeting of Shareholders of QIAGEN N.V.
June 17, 2019
Second Quarter 2019 Results
Third Quarter 2019 Results
Fourth Quarter 2019 Results
Our name together with our logo is registered as a trademark in the United States and a number of other countries: QIAGEN®.
For a complete list of QIAGEN’s trademarks and disclaimers, please refer to QIAGEN’s webpage under www.QIAGEN.com/trademarks_disclaimers.aspx.
In this annual report QIAGEN uses the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. As of February 2019, QIAGEN molecular diagnostics products included 20 FDA (PMA approved or 510k cleared) products, 17 clinical sample concentrator products (14 kits and 3 instruments), 69 EU CE IVD assays, 16 EU CE IVD sample preparation products, 18 EU CE IVD instruments for sample purification or detection, 31 China CFDA IVD assays/sample preparations and 13 China CFDA IVD instruments.
This Annual Report may also contain trade names or trademarks of companies other than QIAGEN.© 2019 QIAGEN, all rights reserved.
This document contains detailed financial information about QIAGEN prepared under generally accepted accounting standards in the U.S. (U.S. GAAP) and included in our Form 20-F annual report filed with the U.S. Securities and Exchange Commission. QIAGEN also publishes an Annual Report under IFRS accounting standards, which is available on our website at www.QIAGEN.com.